10x Genomics, Inc.

NasdaqGS TXG

10x Genomics, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -10.24

10x Genomics, Inc. Price to Earnings Ratio (P/E) is -10.24 on January 14, 2025, a 50.98% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • 10x Genomics, Inc. 52-week high Price to Earnings Ratio (P/E) is -7.84 on July 10, 2024, which is 23.40% above the current Price to Earnings Ratio (P/E).
  • 10x Genomics, Inc. 52-week low Price to Earnings Ratio (P/E) is -23.25 on February 09, 2024, which is -127.06% below the current Price to Earnings Ratio (P/E).
  • 10x Genomics, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -12.79.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
NasdaqGS: TXG

10x Genomics, Inc.

CEO Dr. Serge Saxonov Ph.D.
IPO Date Sept. 12, 2019
Location United States
Headquarters 6230 Stoneridge Mall Road
Employees 1,259
Sector Health Care
Industries
Description

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Similar companies

VCYT

Veracyte, Inc.

USD 41.06

-4.02%

FATE

Fate Therapeutics, Inc.

USD 1.25

-3.10%

BEAM

Beam Therapeutics Inc.

USD 23.30

-8.77%

GH

Guardant Health, Inc.

USD 37.46

-1.68%

TWST

Twist Bioscience Corporation

USD 42.75

-1.91%

StockViz Staff

January 15, 2025

Any question? Send us an email